查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1198087

PGT（植入前基因檢測）市場——增長、趨勢、COVID-19 影響和預測 (2023-2028)

Preimplantation Genetic Testing Market - Growth, Trends, and Forecasts (2023 - 2028)
出版日期: | 出版商: Mordor Intelligence | 英文 110 Pages | 商品交期: 2-3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

PGT（植入前基因檢測）市場預計在預測期內以 10.5% 的複合年增長率增長。

在 COVID-19 期間，植入前基因檢測的採用正在增加，預計這將推動市場增長。 在 2021 年 10 月發表的一篇 NCBI 文章中，PGT（植入前基因檢測）和胚胎學家的專業知識提供安全和輔助生殖技術過程有 COVID-19 感染的既往史，並指出對患者沒有不良影響。 然而，NCBI 於 2022 年 9 月發表的另一篇論文發現，懷孕期□□間感染 COVID-19 的婦女可能會增加產科和新生兒並發症的風險。 此類感染者出現產前並發症的風險將在大流行期間增加對 PGT（植入前基因檢測）的需求。 因此，預計 COVID-19 大流行將促進市場增長，並在研究的預測期內保持同樣的增長勢頭。

市場增長的主要驅動因素是分娩並發症導致的新生兒死亡率高，以及父母對診斷技術進步的認識不斷提高。 近年來，愛德華茲綜合徵等先天性遺傳病和肺炎、哮喘等兒童常見呼吸系統疾病的患病率有所增加。 根據 2021 年 8 月發表的 NCBI 文章，南非先天性異常的機構出生患病率為每 1,000 名活產嬰兒 15.57 例。 根據 2022 年 9 月發布的另一份 NCBI 數據，英國愛德華茲綜合徵的出生患病率從 3600 分之一到 10,000 分之一不等。 據觀察，這些異常幾乎只發生在患有遺傳性疾病的夫婦中，而且主要發生在發達國家。 因此，對早期診斷的需求增加和政府為控制醫療負擔所做的努力預計將推動 PGT（植入前基因檢測）市場。

此外，各種市場參與者發布的產品數量增加預計將在預測期內推動市場增長。 例如，Eurofins Genoma 於 2022 年 9 月推出了無創 niPGT-A。 這是一種無胚胎活檢的植入前遺傳非整倍體篩查試驗。 為 IVF 設施提供高度準確的替代傳統 PGT-A 測試的方法。

因此，預計在預測期內，先天性遺傳病患病率增加和產品發布增加等因素將促進市場增長。 然而，研究人群規模小、倫理問題、昂貴的測試程序、不利的監管框架、開發階段的挑戰等可能會抑制預測期內的市場增長。

植入前基因檢測 (PGT) 市場趨勢

在PGT（植入前基因檢測）市場中，體外受精預後預計在預測期內將佔據較大的市場份額

體外受精 (IVF) 是一種輔助生殖技術，用於治療某些遺傳和不孕不育問題。 IVF預後是通過PGT（Preimplantation Genetic Testing）方法檢查胚胎健康狀況的必要步驟。 因此，PGT（植入前基因檢測）在體外受精的預後中起著重要作用，從而有助於研究部分的生長。 體外受精預測領域有望佔據PGT（胚胎植入前基因檢測）市場的很大份額。 這主要是由於對 PGT（植入前基因檢測）程序的需求增加導致大量體外受精程序。

例如，根據 2022 年 5 月更新的 MayoClinic 文章，全球有 10-12% 的夫婦難以懷孕，預計這一比例在未來幾年內會逐漸增加。 IVF 分別占美國和歐洲所有活產的 1.6% 和 4.5%。 文章還指出，約有25%至35%的不孕婦女患有腹膜下疾病。 盆腔炎 (PID) 是不孕症最常見的原因，而男性精液質量差是導致 20% 夫婦不孕的唯一原因。 因此，難孕人群的沉重負擔和生育率下降促成了這一細分市場的增長。

此外，在預測期內，各種市場參與者推出的產品數量不斷增加，預計將推動所研究細分市場的增長。 例如，2022年7月，GenEmbryonics推出了商業化的全基因組測序測試，有效篩查試管嬰兒胚胎中的所有遺傳病。 這項綜合測試揭示了胚胎的基因組序列，從而可以識別和篩選致病突變。

因此，不孕症增加、對體外受精的偏好增加以及體外受精預後產品發布的增加等因素預計將在預測期內推動研究細分市場的增長。

預計在預測期內北美將佔 PGT（胚胎植入前基因檢測）市場的很大份額

預計北美將主導 PGT（植入前基因檢測）市場。 這種優勢歸因於導致各種遺傳性疾病的染色體異常病例的增加。 此外，該地區消費者意識的提高和重要市場參與者的存在也是該地區市場增長的推動因素。

根據美國疾病控制與預防中心 (CDC) 2021 年 4 月的一份報告，美國每年約有 6,000 名嬰兒患有唐氏綜合症。 同樣，加拿大不列顛哥倫比亞省在 2021 年 2 月發表的一篇文章中指出，在加拿大出生的每 750 個嬰兒中就有一個患有唐氏綜合症。 此外，2021 年 11 月發表在 Facets Journal 上的數據表明，這種罕見疾病影響了大約二分之一的加拿大人，其中大多數有潛在的遺傳原因。 因此，對早期診斷以識別胚胎遺傳異常的需求增加，推動了該地區的市場。

市場參與者的活動增加，例如北美的合作夥伴關係、合併和產品開發聯合研究，預計也將有助於市場的增長。 例如，2022 年 10 月，Ovation Fertility 與 Genomic Prediction 合作，授權 LifeView PGT 基因檢測平台。 Lifeview PGT 提供當今最全面的植入前胚胎基因檢測。

因此，遺傳疾病的高負擔和市場參與者的活躍度增加，加上北美國家對 PGT（植入前基因檢測）意識的增強，將引領該地區的市場在預測期內增長。預計促進增長。

植入前基因檢測 (PGT) 市場競爭對手分析

PGT（植入前基因檢測）市場競爭適中，由幾家主要參與者組成。 主導市場的幾個主要參與者採取了各種策略，例如專注於研發和推出新產品。 目前主導市場的主要公司包括 The Cooper Companies Inc.、Illumina Inc.、Thermo Fisher Scientific Inc.、PerkinElmer Inc.、Bioarray SL。

其他好處

  • Excel 格式的市場預測 (ME) 表
  • 三個月的分析師支持

內容

第一章介紹

  • 研究假設和市場定義
  • 調查範圍

第二章研究方法論

第 3 章執行摘要

第四章市場動態

  • 市場概覽
  • 市場驅動力
    • 帕陶氏綜合症、愛德華氏綜合症和唐氏綜合症等遺傳性疾病的負擔越來越重
    • 政府在提高先進診斷設備開發意識和研發活動方面所做的努力
  • 市場製約因素
    • 研究對像數量少且存在倫理問題
    • 昂貴的檢查程序
    • 不利的監管框架和發展過程中的挑戰
  • 波特的五力分析
    • 供應商的議價能力
    • 買方/消費者議價能力
    • 新進入者的威脅
    • 替代品的威脅
    • 競爭公司之間的敵對關係

第 5 章市場細分（基於價值的市場規模：百萬美元）

  • 按測試類型
    • 植入前遺傳學診斷 (PGD)
    • 植入前基因篩查 (PGS)
  • 按產品/服務
    • 檢驗設備
    • 試劑和耗材
    • 軟件服務
  • 通過申請
    • HLA 分型
    • 體外受精的預後測定
    • 非整倍體篩查
    • 其他應用
  • 最終用戶
    • 醫院和診斷實驗室
    • 產科和不孕不育中心
    • 其他最終用戶
  • 按地區
    • 北美
      • 美國
      • 加拿大
      • 墨西哥
    • 歐洲
      • 德國
      • 英國
      • 法國
      • 意大利
      • 西班牙
      • 其他歐洲地區
    • 亞太地區
      • 中國
      • 日本
      • 印度
      • 澳大利亞
      • 韓國
      • 其他亞太地區
    • 中東
      • 海灣合作委員會
      • 南非
      • 其他中東地區
    • 南美洲地區
      • 巴西
      • 阿根廷
      • 其他南美洲

第六章競爭格局

  • 公司簡介
    • The Cooper Companies Inc.
    • Illumina Inc.
    • Thermo Fisher Scientific Inc.
    • Quest Diagnostics Inc.
    • PerkinElmer Inc.
    • Invitae Corp.
    • Natera Inc.
    • Igenomix Sl
    • Bioarray SL
    • Genea Ltd

第七章市場機會與未來趨勢

簡介目錄
Product Code: 68439

The preimplantation genetic testing market studied was anticipated to grow with a CAGR of 10.5% during the forecast period.

During COVID-19, there was an increasing adoption of the preimplantation of genetic testing, which is expected to drive the market's growth. The NCBI article published in October 2021 mentioned preimplantation genetic testing and embryologist specialization provided safety and assisted reproduction process have not negatively impacted patients with a previous record of COVID-19 infection. However, according to another NCBI article published in September 2022, women with COVID-19 during Pregnancy might have a higher risk of obstetrical and neonatal complications. Such risk of pre-natal complications in the infected patients boosted the demand for preimplantation genetic testing during the pandemic. Thus, the COVID-19 pandemic has increased the market's growth, which is expected to follow the same traction during the forecast period of the study.

The primary factor attributing to the market's growth is a rising awareness among parents regarding advancements in diagnostics, with a massive volume of neonatal deaths due to complications during childbirth. The growing prevalence of congenital genetic diseases like Edwards syndrome and common pediatric respiratory disorders such as pneumonia and asthma has been observed in recent years. As per the NCBI article published in August 2021, the in-facility birth prevalence rate for congenital abnormalities in South Africa was 15.57 per 1,000 live births. Another NCBI published in September 2022 states that the live birth prevalence with Edwards syndrome in the UK ranges from 1 in 3600 to 1 in 10,000. These abnormalities occur almost exclusively in couples with hereditary disorders, which were observed to occur majorly in industrialized nations. Thus, increased demand for earlier diagnosis and government initiatives to control the healthcare burden will likely drive the preimplantation genetic testing market.

Additionally, the increasing product launches by various market players are expected to boost market growth over the forecast period. For instance, Eurofins Genoma launched the niPGT-A, a non-non-invasive, in September 2022. It is an embryo biopsy-free, preimplantation genetic aneuploidy screening test. It provides IVF centers with access to a highly accurate alternative to traditional PGT-A testing.

Thus, the factors such as the growing prevalence of congenital genetic diseases and increasing product launches are expected to contribute to the market's growth over the forecast period. However, the small size of the study population and ethical concerns, costly testing procedures, and unfavorable regulatory framework and challenges during the development stage may restrain the market's growth over the forecast period.

Preimplantation Genetic Testing Market Trends

IVF Prognosis is Expected to Hold a Significant Market Share in the Preimplantation Genetic Testing Market Over the Forecast Period

Invitro fertilization(IVF) is a method of assisted reproduction and treatment for specific genetic and fertility issues. The prognosis for IVF is a necessary procedure to inspect the medical condition of the embryos by preimplantation genetic testing methods. Thus, preimplantation genetic testing plays a crucial role in the IVF prognosis, thereby contributing to the growth of the studied segment. The IVF prognosis segment is expected to account for a significant share of the preimplantation genetic testing market. It is mainly due to the high number of invitro fertilization procedures owing to the increased demand for preimplantation genetic testing procedures.

For instance, according to the MayoClinic article updated in May 2022, globally, 10-12% of couples have difficulty conceiving, which is expected to increase gradually in the coming years. IVF accounts for 1.6% and 4.5% of all US and Europe live births, respectively. Also, the same article quoted that approximately 25% to 35% of infertile women have a subperitoneal disease. Pelvic inflammatory disease (PID) is the most common cause of infertility, and poor semen quality in men is the sole cause of infertility in 20% of couples. Such a high burden of people having difficulty conceiving and a decrease in fertility rates contributes to the segment's growth.

Additionally, the rising product launches by various market players are expected to drive the growth of the studied segment over the forecast period. For instance, in July 2022, GenEmbryonics launched the commercial whole genome sequencing test for effectively screening all genetic diseases in IVF embryos. This comprehensive testing clarifies the embryo's genome sequence, allowing disease-causing mutations to be identified and screened.

Thus, factors such as rising infertility, increasing preference for IVF procedures, and growing product launches for IVF prognosis are expected to drive the growth of the studied segment over the forecast period.

North America is Expected to Hold a Significant Share in the Preimplantation Genetic Testing Market Over the Forecast Period

North America is expected to dominate the preimplantation genetic testing market. The dominance is due to a growing volume of cases of chromosome abnormality leading to various genetic disorders. Additionally, the increasing consumer awareness and the presence of significant market players in this region are also driving factors for the growth of the market in this region.

According to the Centers for Disease Control and Prevention (CDC) report in April 2021, about 6,000 babies born in the US have down syndrome every year. Similarly, the Province of British Columbia, Canada, an article published in February 2021, mentioned that in Canada, one in every 750 live babies born has Down syndrome. Additionally, the data published in Facets Journal in November 2021 noted that rare diseases affect approximately 1 in 12 Canadians, and most have underlying genetic causes. It, in turn, resulted in high demand for earlier diagnoses to identify the genetic defects in embryos, thus driving the market in the region.

The increasing market player's activities, such as partnerships, mergers, and collaborations in North America to develop products, are also expected to contribute to the market's growth. For instance, in October 2022, Ovation Fertility partnered with Genomic Prediction to license the LifeView PGT platform for genetic testing. This Lifeview PGT provides the most comprehensive currently available genetic test of the preimplantation embryo.

Thus, the high burden of genetic diseases and increasing market players' activities, coupled with the rising awareness regarding preimplantation genetic testing in North American countries, is expected to drive the market's growth in this region over the forecast period.

Preimplantation Genetic Testing Market Competitor Analysis

The preimplantation genetic testing market is moderately competitive and consists of several major players. Few of the key players dominating the market are following various strategies like an increased focus on R&D and launching new products. Some of the major companies currently dominating the market are The Cooper Companies Inc., Illumina Inc., Thermo Fisher Scientific Inc., PerkinElmer Inc., and Bioarray SL.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Burden of Genetic Diseases Like Patau Syndrome, Edwards Syndrome, and Down Syndrome
    • 4.2.2 Increased Government Initiatives to Create Awareness and R&D Activities to Develop Advanced Diagnostic Devices
  • 4.3 Market Restraints
    • 4.3.1 Small Size of Study Population and Ethical Concerns
    • 4.3.2 Highly Expensive Testing Procedures
    • 4.3.3 Unfavorable Regulatory Framework and Challenges During Development Stage
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Bargaining Power of Suppliers
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Threat of New Entrants
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION (Market Size by Value - USD million)

  • 5.1 By Test Type
    • 5.1.1 Preimplantation Genetic Diagnosis (PGD)
    • 5.1.2 Preimplantation Genetic Screening (PGS)
  • 5.2 By Product and Service
    • 5.2.1 Instruments
    • 5.2.2 Reagents and Consumables
    • 5.2.3 Software and Services
  • 5.3 By Application
    • 5.3.1 HLA Typing
    • 5.3.2 IVF Prognosis
    • 5.3.3 Aneuploidy Screening
    • 5.3.4 Other Applications
  • 5.4 By End User
    • 5.4.1 Hospitals and Diagnostic Labs
    • 5.4.2 Maternity Centers and Fertility Clinics
    • 5.4.3 Other End Users
  • 5.5 Geography
    • 5.5.1 North America
      • 5.5.1.1 United States
      • 5.5.1.2 Canada
      • 5.5.1.3 Mexico
    • 5.5.2 Europe
      • 5.5.2.1 Germany
      • 5.5.2.2 United Kingdom
      • 5.5.2.3 France
      • 5.5.2.4 Italy
      • 5.5.2.5 Spain
      • 5.5.2.6 Rest of Europe
    • 5.5.3 Asia-Pacific
      • 5.5.3.1 China
      • 5.5.3.2 Japan
      • 5.5.3.3 India
      • 5.5.3.4 Australia
      • 5.5.3.5 South Korea
      • 5.5.3.6 Rest of Asia-Pacific
    • 5.5.4 Middle East
      • 5.5.4.1 GCC
      • 5.5.4.2 South Africa
      • 5.5.4.3 Rest of Middle East
    • 5.5.5 South America
      • 5.5.5.1 Brazil
      • 5.5.5.2 Argentina
      • 5.5.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 The Cooper Companies Inc.
    • 6.1.2 Illumina Inc.
    • 6.1.3 Thermo Fisher Scientific Inc.
    • 6.1.4 Quest Diagnostics Inc.
    • 6.1.5 PerkinElmer Inc.
    • 6.1.6 Invitae Corp.
    • 6.1.7 Natera Inc.
    • 6.1.8 Igenomix Sl
    • 6.1.9 Bioarray SL
    • 6.1.10 Genea Ltd

7 MARKET OPPORTUNITIES AND FUTURE TRENDS